Verge Genomics a biotechnology company using artificial intelligence to develop therapies for diseases of the nervous system announced on Friday a four-year partnership with AstraZenecas rare disease unit Alexion to identify new drug targets. As part of the agreement Verge will receive up to 42 million in upfront equity and nearterm payments